BRPI0922760A2 - derivados de 6-ciclo amino -3-(1h-pirrolo [2,3-b] piridin -4-il) imidazo [1,2-b]- piridazina, o respectivo preparo e a respectiva aplicação em terapêutica - Google Patents

derivados de 6-ciclo amino -3-(1h-pirrolo [2,3-b] piridin -4-il) imidazo [1,2-b]- piridazina, o respectivo preparo e a respectiva aplicação em terapêutica

Info

Publication number
BRPI0922760A2
BRPI0922760A2 BRPI0922760-1A BRPI0922760A BRPI0922760A2 BR PI0922760 A2 BRPI0922760 A2 BR PI0922760A2 BR PI0922760 A BRPI0922760 A BR PI0922760A BR PI0922760 A2 BRPI0922760 A2 BR PI0922760A2
Authority
BR
Brazil
Prior art keywords
group
cycloamino
pyrrolo
imidazo
pyridin
Prior art date
Application number
BRPI0922760-1A
Other languages
English (en)
Inventor
Pacaud Christophe
Puech Frédéric
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of BRPI0922760A2 publication Critical patent/BRPI0922760A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0922760-1A 2008-12-01 2009-11-30 derivados de 6-ciclo amino -3-(1h-pirrolo [2,3-b] piridin -4-il) imidazo [1,2-b]- piridazina, o respectivo preparo e a respectiva aplicação em terapêutica BRPI0922760A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0806723 2008-12-01
FR0806723A FR2939134A1 (fr) 2008-12-01 2008-12-01 Derives de 6-cycloamino-3-(1h-pyrrolo°2,3-b!pyridin-4-yl) imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique
PCT/FR2009/052336 WO2010063929A1 (fr) 2008-12-01 2009-11-30 DERIVES DE 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-b]PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE

Publications (1)

Publication Number Publication Date
BRPI0922760A2 true BRPI0922760A2 (pt) 2018-11-06

Family

ID=40383902

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922760-1A BRPI0922760A2 (pt) 2008-12-01 2009-11-30 derivados de 6-ciclo amino -3-(1h-pirrolo [2,3-b] piridin -4-il) imidazo [1,2-b]- piridazina, o respectivo preparo e a respectiva aplicação em terapêutica

Country Status (27)

Country Link
US (1) US8546395B2 (pt)
EP (1) EP2370446B1 (pt)
JP (1) JP5677309B2 (pt)
KR (1) KR20110082094A (pt)
CN (1) CN102232079A (pt)
AR (1) AR074237A1 (pt)
AU (1) AU2009323968A1 (pt)
BR (1) BRPI0922760A2 (pt)
CA (1) CA2743560A1 (pt)
CY (1) CY1117529T1 (pt)
DK (1) DK2370446T3 (pt)
ES (1) ES2563085T3 (pt)
FR (1) FR2939134A1 (pt)
HR (1) HRP20160173T1 (pt)
HU (1) HUE028525T2 (pt)
IL (1) IL213208A0 (pt)
MX (1) MX2011005808A (pt)
PA (1) PA8849801A1 (pt)
PL (1) PL2370446T3 (pt)
PT (1) PT2370446E (pt)
RS (1) RS54656B1 (pt)
RU (1) RU2011126981A (pt)
SG (1) SG172757A1 (pt)
SI (1) SI2370446T1 (pt)
TW (1) TW201033209A (pt)
UY (1) UY32280A (pt)
WO (1) WO2010063929A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2681162C (en) * 2007-03-15 2015-11-24 Novartis Ag Benzyl and pyridine derivatives as modulators of hedgehog pathway
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
WO2012175591A1 (en) * 2011-06-22 2012-12-27 Bayer Intellectual Property Gmbh Heterocyclyl aminoimidazopyridazines
WO2021190615A1 (en) * 2020-03-27 2021-09-30 Gritscience Biopharmaceuticals Co., Ltd. Compounds as casein kinase inhibitors
CA3235146A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE428711T1 (de) 2003-12-11 2009-05-15 Aventis Pharma Inc Substituierte 1h-pyrroloä3,2-b, 3,2-c und 2,3- cüpyridin-2-carbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i- epsilon
US7750000B2 (en) * 2005-09-02 2010-07-06 Bayer Schering Pharma Ag Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
DE102005042742A1 (de) * 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
AR064420A1 (es) * 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
AR066477A1 (es) * 2007-05-09 2009-08-19 Novartis Ag Imidazopiridazinas sustituidas como inhibidores de cinasa de lipido
PE20090288A1 (es) * 2007-05-10 2009-04-03 Smithkline Beecham Corp Derivados de quinoxalina como inhibidores de la pi3 quinasa
AR067326A1 (es) * 2007-05-11 2009-10-07 Novartis Ag Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
FR2918061B1 (fr) * 2007-06-28 2010-10-22 Sanofi Aventis Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
FR2918986B1 (fr) * 2007-07-19 2009-09-04 Sanofi Aventis Sa Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
CY1117529T1 (el) 2017-04-26
PL2370446T3 (pl) 2016-05-31
SG172757A1 (en) 2011-08-29
AR074237A1 (es) 2010-12-29
FR2939134A1 (fr) 2010-06-04
AU2009323968A1 (en) 2010-06-10
US8546395B2 (en) 2013-10-01
MX2011005808A (es) 2011-10-11
DK2370446T3 (en) 2016-02-22
JP5677309B2 (ja) 2015-02-25
CA2743560A1 (fr) 2010-06-10
SI2370446T1 (sl) 2016-03-31
IL213208A0 (en) 2011-07-31
RU2011126981A (ru) 2013-01-10
JP2012510453A (ja) 2012-05-10
CN102232079A (zh) 2011-11-02
US20120010208A1 (en) 2012-01-12
PT2370446E (pt) 2016-03-22
ES2563085T3 (es) 2016-03-10
TW201033209A (en) 2010-09-16
HRP20160173T1 (hr) 2016-03-25
PA8849801A1 (es) 2010-07-27
KR20110082094A (ko) 2011-07-15
RS54656B1 (sr) 2016-08-31
WO2010063929A1 (fr) 2010-06-10
EP2370446A1 (fr) 2011-10-05
UY32280A (es) 2010-06-30
EP2370446B1 (fr) 2015-11-25
HUE028525T2 (hu) 2016-12-28

Similar Documents

Publication Publication Date Title
BR112013015959A2 (pt) Derivados de 2-arilimidazo [1,2-b] piridazina, 2- fenilimidazo [1,2-a] piridina, e 2-fenilimidazo [1,2-a] pirazina.
PH12013500742A1 (en) Imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives as jak inhibitors
WO2009037394A3 (fr) DERIVES DE 6-CYCLOAMINO-S-(PYRIDAZIN-YL)IMIDAZO[1,2-b]-PYRIDAZINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE.
ZA201204028B (en) Imidazo[1.2-a]pyridine compounds, sysnthesis thereof, and methods of using same
EP2387315A4 (en) IMIDAZO- [1,2-A-] PYRIDINES AND IMIDAZO- [1,2-B-] PYRIDAZINE AS MARK HEMMER
IL219424A0 (en) IMIDAZO [1,2-b] PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
SI2419428T1 (sl) Imidazo (1,2-a) piridin derivati kot FGFR kinaza inhibitorji za uporabo v terapiji
FR2918061B1 (fr) Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
WO2008121687A3 (en) Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
ZA201003050B (en) [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or pyridin-2-yle derivatives as protein kinase c-theta
ZA201106599B (en) Pyrrolo [2,3-b] pyridine derivatives for the inhibition of raf kinases
NZ703111A (en) Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
AP2453A (en) Pyrazolo(3,4-B) pyridine derivatives as phosphodiesterase inhibitors
EP2986300A4 (en) 3,5- (UN) SUBSTITUTED 1H-PYRROLO [2,3-B] PYRIDINE, 1H-PYRAZOLO [3,4-B] PYRIDINE AND 5H-PYRROLO [2,3-B] PYRAZIN DUAL ITK AND -JAK3-KINASEINHIBITORS
IL211311A0 (en) Pyrrolo [1,2-b] pyridazine derivatives and their use as hif modulators
IL215074A0 (en) Substituted imidazo[1,2-a]pyridine derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors
BR112012002110A2 (pt) derivados de pirrolo[1,2-b]piridazina como inibidores de janus cinase
ZA201307511B (en) Pyrido [2,3-b] pyrazine derivatives and their therapeutical uses
ZA200907679B (en) 9- (pyrazol- 3 -yl) -9h-purine-2 -amine and 3- (pyrazol-3-yl) -3h-imidazo [4, 5-B) pyridin-5-amine derivatives and their use for the treatment of cancer
MX352927B (es) Derivados de 1h-pirrolo [2,3-b] piridina y su uso como inhibidores de quinasa.
WO2011156786A8 (en) 6-(ethynyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
BRPI0922760A2 (pt) derivados de 6-ciclo amino -3-(1h-pirrolo [2,3-b] piridin -4-il) imidazo [1,2-b]- piridazina, o respectivo preparo e a respectiva aplicação em terapêutica
BRPI0917939A2 (pt) derivados de 2-alquil-6-cicloamino-3-(piridin-4-il) imidazo[1,2-b]-piridazina, preparação dos mesmos e aplicação dos mesmos em terapia
IL217294A0 (en) Novel 2,3 - dihydro -1h -imidazo (1,2-a)pyrimidin -5-one derivatives, preparation thereof, and pharamceutical use thereof
IL206673A0 (en) Imidazo[1,2-a]pyridine-2-carboxamide derivatives, their preparation and their therapeutic application

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2497 DE 13-11-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.